The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldman, C. M.
Right arrow Articles by Hertl, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldman, C. M.
Right arrow Articles by Hertl, M.
The Journal of Immunology, 2004, 172: 3883-3892.
Copyright © 2004 by The American Association of Immunologists

T Cell Recognition of Desmoglein 3 Peptides in Patients with Pemphigus Vulgaris and Healthy Individuals1

Christian M. Veldman2,*, Kerstin L. Gebhard2,*, Wolfgang Uter{dagger}, Ralf Wassmuth{ddagger}, Joachim Grötzinger§, Erwin Schultz* and Michael Hertl3,*

Departments of * Dermatology, and {dagger} Medical Informatics, Biometry, and Epidemiology, University of Erlangen-Nürnberg, Erlangen, Germany; {ddagger} Institute for Transplantation Diagnostics and Cell Therapeutics, Düsseldorf University Medical Center, Düsseldorf, Germany; and § Institute of Biochemistry, University of Kiel, Kiel, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Pemphigus vulgaris is a severe autoimmune disease caused by autoantibodies against the cutaneous adhesion molecule, desmoglein 3 (Dsg3). The aim of this study was to characterize the specificity of autoreactive Th cells, which presumably regulate Dsg3-specific autoantibody production. Ninety-seven Th1 and Th2 clones isolated from 16 pemphigus patients and 12 HLA-matched healthy donors recognized the Dsg3 peptides, DG3(78-94), DG3(96-112), DG3(189-205), DG3(205-221), and DG3(250-266). Peptide DG3(96-112), and to a lesser extent DG3(250-266), was recognized by the majority of T cells from patients and healthy donors in association with HLA-DRB1*0402 and DQB1*0503 which were prevalent in the pemphigus patients and Dsg3-responsive healthy donors. Analyzing the V{beta}-chain of the TCR of the DG3(96-112)-specific T cells showed no restricted TCR usage. Peptides DG3(342-358) and DG3(376-392) were exclusively recognized by T cell clones (n = 13) from patients while DG3(483-499) was only recognized by T cell clones (n = 3) from a healthy donor. All Dsg3 peptides contained conserved amino acids at relative positions 1, 4, and 6; amino acids with a positive charge at position 4 presumably represent anchor motifs for DRB1*0402. These findings demonstrate that T cell recognition of distinct Dsg3 peptides is restricted by distinct HLA class II molecules and is independent from the development of pemphigus vulgaris.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Pemphigus vulgaris (PV)4 is considered as a paradigm of an autoantibody (autoAb)-mediated autoimmune disease of the skin associated with a loss of epidermal cell-cell adhesion caused by autoAb against the desmosomal adhesion molecules, desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1) (1, 2). The pathogenic role of Dsg-specific autoAb has been clearly established by different investigators in several in vitro and in vivo models (3, 4, 5). Moreover, Dsg3 deficient mice express a phenotype with mucosal blisters/erosions that clearly resembles the clinical findings seen in PV (6). Recently, additional autoantigens that are recognized by PV sera have been identified; their pathogenic relevance is not yet fully clear. Two potential new target Ags of PV belong to the group of cholinergic receptors. Pemphaxin is an annexin homologue that binds acetylcholine (7) and the {alpha}9 acetylcholine receptor is also present on keratinocytes (8). In addition, a novel member of the desmoglein family, Dsg4, was identified which shows great homology with Dsg3 for the first three extracellular domains (ECD) and was found to be recognized by PV sera (9). The precise role that autoAb against Dsg4 play in the pathogenesis of PV needs to be elucidated.

Clinically, PV is a potentially life threatening autoimmune bullous disorder characterized primarily by mucosal lesions (generally when IgG autoAb against Dsg3 are present), and mucocutaneous blisters and erosions (when IgG autoAb against both Dsg3 and Dsg1 are present) (10, 11). The titers of autoAb against Dsg3 and Dsg1 strongly correlate with activity of disease in individual patients (10, 12). AutoAb production in PV is polyclonal and most autoAb are of the IgG4 subclass in patients with active disease, while patients with chronic disease often have autoAb of the IgG1 and IgG4 subtypes (13, 14). AutoAb against Dsg1 and Dsg3 are capable, independent of complement activation, to induce the pathology of pemphigus by interfering with the function of desmosomes that mediate adhesion between epidermal keratinocytes (3, 15).

PV is associated with the HLA class II allele, HLA-DRB1*0402, particularly in Jewish patients (16), whereas DRB1*14/DQB1*0503 is prevalent in non-Jewish patients (17, 18). Recent evidence suggests that these HLA class II alleles are involved in the presentation of Dsg3 peptides to autoreactive T cells in PV patients (19, 20, 21, 22). Autoreactive Th cells are presumably critical for the induction and regulation of Ab production (23). Dsg3-reactive Th1 and Th2 cells have been identified by several studies in PV patients. However, their phenotype, cytokine profile, immunogenetic restriction, and epitope specificity varied (19, 20, 21). In PV patients, both Dsg3-reactive Th1 and Th2 cells were identified that recognized portions of the ECD of Dsg3 in the context with PV-associated HLA class II alleles (20, 21, 22). Autoreactive Th1 cells reactive to Dsg3 were also isolated from the blood of healthy carriers of the PV-associated HLA class II alleles, HLA-DRB1*0402 and DQB1*0503 (21, 22).

The purpose of this study was to identify Dsg3 peptides that arerecognized by autoreactive Th cells of PV patients. Because T cell recognition of Dsg3 was also detected in HLA class II-matched healthy individuals, the peptide specificity of Dsg3-reactive T cell clones (TCC) from these control donors was also studied. In a cohort of 16 PV patients and 12 healthy donors, autoreactive Th cells recognized a limited set of peptides located in the ECD of Dsg3. Two of these peptides were recognized by the majority of TCC of patients and healthy controls. Moreover, T cell recognition of Dsg3 peptides was predominantly restricted by HLA-DRB1*0402 and DQB1*0503. These observations strongly suggest that T cell recognition of Dsg3 peptides both in PV patients and in healthy individuals is tightly restricted by distinct HLA class II alleles and is directed against a limited set of epitopes located in the ECD of Dsg3.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Patients and healthy controls

Heparinized blood samples (40–80 ml) were obtained from 16 PV patients who were seen at the Department of Dermatology at the University of Erlangen (Erlangen, Germany) and from 12 healthy controls. Both patients and healthy donors gave written informed consent to participate in this study. The clinical diagnosis of PV was confirmed by direct immunofluorescence microscopy (epidermal intercellular IgG and/or C3 deposits in perilesional skin), histopathology, indirect immunofluorescence microscopy (intercellular IgG binding to epithelial cells of monkey esophagus), and the presence of circulating autoAb against Dsg3, tested by a commercial Dsg3-ELISA (MDL, Naka-ku Nagoya, Japan). Patients were divided into three groups depending on the stage of disease (Table I). Acute onset PV was defined as the de novo development of blisters/erosions on previously unaffected mucosal surfaces and/or skin; all of these patients had not yet received immunosuppressive therapy. Chronic active PV was defined as the expansion/persistence of existing blisters or erosions on mucosal surfaces and/or skin; some of these patients had already received immunosuppressive treatment. Patients with remittent PV had not experienced new mucosal blisters/erosions for 6 mo or more before the study. Some of the studied PV patients had been already included in a recent study (22). However, the Dsg3-specific TCC that were characterized in the present investigation were newly generated for this purpose.


View this table:
[in this window]
[in a new window]
  		Table I. Clinical presentation, HLA class II alleles, autoAb titers and T cell response to Dsg3 peptides of the studied PV patients

 
HLA class II genotyping was performed in all patients and controls. The determination of HLA-DRB1 and DQB1 alleles was conducted at high resolution by enzyme-linked-probe-hybridization-assay (Biotest Diagnostics, Dreieich, Germany) using locus-specific PCR products as templates.

Human recombinant Dsg3

The recombinant protein PVhis used in this study is a fusion protein, consisting of the ECD1–5 of Dsg3 linked to an E-tag and a histidine-tag (12). For the production of Dsg3 protein, recombinant PVhis baculovirus was amplified in SF21 insect cells as described previously (21, 24). For protein production, High-Five insect cells were inoculated for 4 days with the baculovirus at a multiplicity of infection of 10. Dsg3 protein was purified from culture supernatants by affinity chromatography over Ni-NTA-linked (nickel-nitrilotriacetic) agarose (Qiagen, Hilden, Germany) as recently described (22).

Isolation of Dsg3 reactive Th1 and Th2 cells by MACS cytokine secretion assay

PBMC (4–8 x 107) of PV patients and controls were cocultured with Dsg3 (10 µg PVhis/ml) for 16 h in vitro. For isolation and quantification of Dsg3-autoreactive Th1 and Th2 cells, a MACS cytokine secretion assay for IFN-{gamma} and IL-4 (Miltenyi Biotec, Bergisch-Gladbach, Germany) was performed according to standardized procedures (25). After 16 h in vitro culturing, high affinity anti-cytokine Ab were added that bound to the surface of in vitro activated cytokine-secreting T cells. Afterward, the cells were labeled with a secondary magnetic bead-coupled Ab for specific enrichment of IL-4 and IFN-{gamma} secreting T cells. The labeled cells were separated with MACS columns into IFN-{gamma} secreting (Th1) and IL-4 (Th2) T cells and finally counted with a hemocytometer as recently described (25).

Following MACS secretion assay, isolated autoreactive T cells were cloned by limiting dilution in 96-well plates (BD-Falcon, Heidelberg, Germany), according to a standard protocol (26). T cells were cultured and expanded with RPMI 1640 (Life Technologies, Karlsruhe, Germany), supplemented with 2% heat-inactivated PHS (ICN Pharmaceuticals, Irvine, CA), 8% heat-inactivated FCS (PAA, Cölbe, Germany), 100 U/ml penicillin, 100 µg/ml streptomycin, 20 mM L-glutamine, nonessential amino acids, and 100 U/ml IL-2 (Biotest Pharma, Dreieich, Germany). For long term culture, TCC were stimulated periodically with 1% PHA (Sigma-Aldrich, Taufkirchen, Germany) and x-irradiated (50 Gy) PBMC as APC.

Proliferative in vitro assays with Dsg3-reactive TCC

A total of 5 x 105 TCC were cultured in duplicate with 5 x 105 x-irradiated human EBV-transformed autologous B lymphoblastoid cell lines (B-LCL) (80 Gy) or PBMC (50 Gy) as APC and Dsg3 (100 nM) or Dsg3 peptides (5 µM each) in RPMI 1640 with 10% PHS in 96-well round-bottom microtiter plates (BD-Falcon) for 48 h at 37°C in 5% CO2. For the final 18 h, 0.6 µCi [3H]thymidine (DuPont, Mechelen, Belgium) were added to each microculture. T cell proliferation was counted in a cell harvester (BD-Falcon) and expressed as stimulation index (SI), which is the ratio of [3H]thymidine uptake (cpm) in cultures with Ag and cultures without Ag. SI values >2 were considered to represent a significant proliferative response.

Identification of immunodominant T cell peptides of Dsg3

A total of 97 TCC were screened for Dsg3 peptide reactivity using 111 17mer peptides of Dsg3 that encompassed the entire ECD of Dsg3 and were staggered by 5 aa residues as previously described (21). These peptides were synthesized by pepset technique (Chiron Mimotopes, San Diego, CA) resulting in a purity greater than 65% as determined by HPLC. All 111 Dsg3-peptides were sib-selected for the mapping of T cell epitopes. Identified immunodominant T cell peptides were resynthesized using F-moc chemistry (Institute of Biochemistry, University of Erlangen, Erlangen, Germany) resulting in a purity of at least 95%. Lyophilized peptides were reconstituted in H2O and 0.2% acetic acid at 2 mg/ml and stored at -80°C. Each individual peptide was used in vitro at 5 µM, which was found to be an optimal stimulatory concentration for most of the TCC.

HLA restriction assay of Dsg3-responsive TCC

A total of 5 x 104 cloned T cells were cocultured with 5 x 104 x-irradiated (80 Gy) autologous or HLA-matched B-LCL cells and 100 nM Dsg3 or 5 µM Dsg3 peptides for 72 h. T cell proliferation was determined by the incorporation of [3H]thymidine (DuPont) that was added for the final 18 h of the culture (26). For HLA blocking experiments, mAb against HLA-DR (clone L243), HLA-DQ (clone SK10), or HLA-DP (clone B7/21) (BD PharMingen, Heidelberg, Germany) were added at 250 ng/ml to the cultures with Dsg3-reactive TCC and B-LCL as APC. Again, the proliferative T cell response to Dsg3 was determined by the incorporation of [3H]thymidine (DuPont) that was added for the final 18 h of culture.

Analysis of potential HLA class II binding motifs of identified Dsg3 peptides

Three-dimensional models of the two HLA class II alleles, HLA-DRB1*0402 and HLA-DQB1*0503, were built by using the x-ray structure of the MHC II/peptide complex (Protein Data Bank accession code 1seb) as a template. Sequence alignments of the molecules were generated and according to this alignment, amino acid residues were exchanged in the template using a database-search approach included in the software package WHATIF (27). Finally, the structural models were energy-minimized using the steepest descent algorithm implemented in the GROMOS force field (28). The structural representations were generated with the Grasp program (29). All programs were run on a Silicon Graphics Indigo (Silcon Graphics, Mountain View, CA) (29).

Analysis of the TCR V{beta} region (TCRBV)

Total RNA was extracted from TCC using the RNAeasy kit according to the manufacturer's specifications (Qiagen). First-stranded cDNA was synthesized by reverse transcription using AMV reverse transcriptase following the manufacturer's protocol (Promega, Mannheim, Germany). Complementary DNA was quantified using ultraviolet spectrometry, and diluted to 50 ng/µl with dH2O. TCR were amplified by PCR using a 5'-sense primer specific for each of the 24 TCRBV families (and two subfamilies) and a conserved 3'-anti-sense TCR conserved {beta} region (TCRBC) primer. Two and a half microtiters (100 ng) of cDNA were combined with 22.5 µl of reaction mix containing 1x PCR buffer (Roche, Mannheim, Germany), 160 mM desoxyribonucleoside triphosphate (Amersham Pharmacia Biotech, Freiburg, Germany), 0.4 mM of the appropriate TCRBV-specific primer, 0.4 mM of TCRBC-specific primer, and 5 U Taq DNA polymerase (Roche, Mannheim, Germany). PCR amplification was conducted using 25 cycles of 94°C for 1 min, 68°C for 2 min, and 72°C for 3 min in a DNA thermocycler (Personal Cycler; Biometra, Goettingen, Germany, and Cyclone 25; Peqlab, Erlangen, Germany). The TCRBV gene usage was identified by the presence of a single PCR product from the panel of 26 TCRBV-TCRBC primer reactions on an agarose gel.

Statistical analyses

In addition to descriptive uni- and bivariate statistics, several statistical tests were performed as follows: The association between T cell responses against Dsg3 (SI >= 2) and defined Dsg3 peptides was assessed with Fisher’s exact test. Correlation was analyzed using the Spearman rank correlation coefficient. Differences between the three groups of HLA type regarding Th1/Th2 ratio were statistically tested with the Kruskal-Wallis test. In view of sparse and skewed data, which render asymptomatic test results unreliable, a Monte Carlo estimate of the exact p value was computed. The association between case status (related here to a TCC being derived from a PV patient vs a healthy control) and peptide stimulation, controlling for HLA status, was tested with logistic regression analysis. The strength of association was quantified with the odds ratio; accompanying 95% confidence intervals was calculated using the profile likelihood method. For data analysis, the statistical software package SAS (version 8.2; SAS Institute, Cary, NC) was used.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Dsg3-reactive Th1 and Th2 cells in PV patients and healthy individuals

A total of 16 patients and 12 healthy controls were included in this study. The majority (81%) of the studied PV patients expressed either HLA-DRB*0402 (31%) or HLA-DQB1*0503 (50%), which represent HLA class II alleles known to be prevalent in PV (Table I). All of the PV patients mounted detectable Th1 and Th2 responses against Dsg3 ranging from 2.8 to 37.6 cells/105 PBMC and 3.2 to 9.6 cells/105 PBMC, respectively (Fig. 1), which is in line with recent observations from our group (22): Statistical analysis revealed that there was no significant difference between the Th1 (chronic vs acute; p = 0.06) and Th2 frequency in acute onset, chronic active or remittent PV (Fig. 1).



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 1. Frequency of Dsg3-responsive autoreactive Th1 and Th2 cells in PV patients and healthy controls. Autoreactive Th1 cells (secreting IFN-{gamma}) and Th2 cells (secreting IL-4) were selected and isolated by the MACS cytokine secretion assay (see Materials and Methods) after short term culture of PBMC with Dsg3. Shown is the frequency (mean ± SD) of Dsg3-responsive Th1 and Th2 cells from a total of 16 PV patients and of Th1 cells from a total of 12 healthy donors.

 
Seven of 12 (58%) healthy donors carried the PV-prevalent HLA class II alleles, HLA-DRB1*0402 and/or HLA-DQB1*0503, while the five remaining individuals expressed PV-unrelated HLA class II alleles (Table II). Although none of the healthy donors had circulating autoAb against Dsg3, all of the carriers of the PV-associated HLA class II alleles, HLA-DRB1*0402 and HLA-DQB1*0503, exhibited T cell reactivity against Dsg3, which was predominantly of Th1 type (Fig. 1) since Dsg3-reactive Th2 cells were not identified above the detection limit of 0.8 T cells/105 PBMC (Fig. 1). In a few controls, MACS-derived Th2 cells which were below the detection limit of the assay were grown up in bulk cultures before limiting dilution resulting in the derivation of a total of 13 TCC of the Th2 type.


View this table:
[in this window]
[in a new window]
  		Table II. HLA class II alleles and T cell response to Dsg3/Dsg3 peptides of the studied healthy individuals

 
Mapping of T cell epitopes of Dsg3

A total of 97 Th1 and Th2 clones that were responsive to Dsg3 were isolated by MACS cytokine secretion assay from both PV patients and healthy controls (Table I and II). Dsg3 T cell reactivity was detected in all of the studied PV patients, independent from their clinical activity of disease and their immunosuppressive treatment, as well as in healthy individuals (Table I and II). Noteworthy, the majority (86%) of the TCC recognized a limited set of only eight Dsg3 peptides (Table III); the epitope specificity of the remaining 14 Dsg3-responsive TCC was not identified by this approach. Five Dsg3 peptides, DG3(78-94), DG3(96-112), DG3(189-205), DG3(205-221), and DG3(250-266), residing within the first ECD1–2 of Dsg3 were recognized by autoreactive Th1 and Th2 clones from both PV patients and healthy donors (Fig. 2, A and B; Table I and II). Two additional Dsg3 peptides, DG3(342-358) and DG3(376-392) residing in the ECD3 were recognized by TCC (n = 13) from three PV patients but not by the healthy donors. Peptide DG3(483-499) residing in the ECD5 of Dsg3 was exclusively recognized by TCC (n = 3) from a healthy donor.


View this table:
[in this window]
[in a new window]
  		Table III. Identified Dsg3 T cell peptides

 


View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 2. Dsg3-responsive Th cells from PV patients and healthy individuals recognize a limited set of epitopes within the ECD1–5 of Dsg3. Shown on the ordinate is the number of individuals (patients and healthy controls) that showed a proliferative T cell response to defined Dsg3 peptides (as shown on the abscissa). A, The numbers of Dsg3 peptide responsive Th1 and Th2 clones are indicated above the bars. B, Shown below are the regions of the ECD1–5 of Dsg3 where the peptides are located.

 
In addition, a total of 21 Dsg3-responsive TCC were isolated from three PV patients and five healthy donors who did not carry any of the PV-associated HLA class II alleles (Table I and II). In these PV patients, eight TCC responded to Dsg3 peptide DG3(96-112) while the remaining four were specific for DG3(250-266). In the group of the healthy controls, seven TCC from the donors Co7 and Co12 were specific for DG3(96-112) while two TCC from donor Co5 were responsive to DG3(483-499) (Table II). Noteworthy, all the healthy controls that were responsive to DG3(96-112) were positive for HLA-DQB*0301 which is homologous to DQB1*0503 (Table II). In the following analyses, the TCC were considered as observational unit.

Identification of Dsg3 T cell peptides

The majority of the PV patients and healthy controls responded to the Dsg3 peptides, DG3(96-112) and DG3(250-266), located in the ECD1–2 of Dsg3, respectively (Fig. 2, A and B). Noteworthy, DG3(96-112) and DG3(250-266) were also recognized by most of the generated Dsg3-responsive TCC. In detail, 46 of 97 (47.4%) TCC responded to peptide DG3(96-112), 11 of 97 TCC (11%) to DG3(250-266); 7 of 97 TCC (7%) each to DG3(205-221), DG3(342-358), or DG3(376-392); 5 of 97 TCC (5%) to DG3(189-205); and 7 of 97 TCC (7%) to DG3(78-94) and DG3(483-499), respectively (Fig. 2, A and B). There was no association between the case status (related here to a TCC being derived from a PV patient vs a healthy control) and global Dsg3 peptide recognition, controlling for HLA status as tested with logistic regression analysis (data not shown). A summary for all 97 TCC is shown in Tables I and II.

A significant association between the proliferative responses of TCC to distinct Dsg3 peptides and case status of TCC, controlling for HLA status, was found only for peptide DG3(96-112) (odds ratio 2.68, 95% confidence intervals: 1.08–6.94); as mentioned this refers to clones as observations/observational units, and not subjects (Fig. 3, A and B). This finding strongly suggests that this particular Dsg3 peptide is indeed preferentially recognized by autoreactive T cells. In contrast, there was no association between T cell reactivity to Dsg3 and responsiveness to any of the other identified Dsg3 peptides (Fig. 3A).



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 3. Relationship between T cell recognition of recombinant Dsg3 protein and reactivity to distinct Dsg3 peptides. A, Shown is a comparative analysis of the proliferative response of the total of generated 97 Dsg3-specific TCC to Dsg3 protein and to one of the eight identified Dsg3 peptides. B, A significant positive correlation between T cell reactivity to Dsg3 and the peptide DG3(96-112) was observed; p = 0.0175.

 
Dsg3 peptide recognition of autoreactive Th1 and Th2 cells

The peptides DG3(78-94), DG3(189-205), and DG3(205-221) were only recognized by three TCC of the Th1 type isolated from three controls, while peptides DG3(78-94), DG3(189-205), and DG3(376-392) were only recognized by seven Th2 clones isolated from three PV patients (Fig. 2A). However, no significant association between these Th1 or Th2 cells and Dsg3 peptide recognition to one of these peptides was observable due to the low numbers of TCC and thus limited power of the analysis. All other peptides were recognized equally by TCC of Th1 or Th2 type isolated from patients as well as from healthy individuals.

Differential T cell responsiveness to Dsg3 peptides

Even though all the Dsg3-responsive TCC were MACS-selected after short term in vitro stimulation with recombinant Dsg3, their responsiveness toward Dsg3 and Dsg3 peptides varied upon prolonged in vitro culture (1–2 mo). Three differential patterns of T cell recognition were found (Fig. 4): 1) TCC responsiveness to both, recombinant Dsg3 and a specific Dsg3 peptide, 2) TCC responsive to a specific Dsg3 peptide but not to recombinant Dsg3, and 3) TCC responsive only to recombinant Dsg3 but not to one of 111 17mer peptides that represent regions within the ECD1–5 of Dsg3.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 4. Differential Th cell recognition of recombinant Dsg3 protein and Dsg3 peptides. Shown is the proliferative response of Dsg3-responsive TCC with autologous PBMC as APC as determined by the uptake of [3H]thymidine (cpm ± SD). Three differential patterns of T cell recognition of Dsg3 protein/Dsg3 peptides were found as shown: The TCC PV7.1 responded to both, recombinant Dsg3 (100 nM) and peptide DG3(342-358) with a maximal proliferation at 10–25 µM (A). The TCC PV10.2 showed a proliferative response to peptide DG3(96-112) but not to recombinant Dsg3 (100 nM); this TCC showed maximal proliferation to DG3(96-112) at 2.5–5 µM (B). The TCC PV11.2 was responsive only to recombinant Dsg3 (100 nM) but not to 1 of 111 17mer peptides that span the ECD1–5 of Dsg3 (C).

 
Fig. 4 shows the distinct patterns of proliferative responses of three representative TCC PV7.1, PV10.2, and PV11.2, derived from three different PV patients. Like the majority (58 of 97) of the generated Dsg3-responsive TCC, TCC PV7.1 showed a vigorous proliferative response to both recombinant Dsg3 (100 nM) and to Dsg3 peptide DG3(342-358) with a maximal proliferation at a peptide concentration of 10–25 µM (Fig. 4A). A significant fraction of the TCC (39 of 97), as shown with the DG3(96-112)-responsive TCC PV10.2, did not proliferate in response to recombinant Dsg3 protein (100 nM) despite responsiveness to a distinct Dsg3 peptide (derived from two different manufactors); their proliferative response usually reached a maximum at a lower peptide concentration, i.e., 2.5–5 µg/ml (Fig. 4B). Finally, a total of 14 additional Dsg3-specific TCC, stimulated by recombinant Dsg3 at 100 nM, were not responsive to any of the used 17mer peptides that span the entire ECD1–5 of Dsg3, as shown for the representative TCC PV 11.2 (Fig. 4C). These findings strongly suggest that autoreactive T cell responses against Dsg3 are tuned not only by differential epitope recognition but also by differential affinity to Dsg3 peptides.

HLA class II restriction of Dsg3 peptide recognition

In light of the preferential detection of HLA-DRB1*0402 and HLA-DQB1*0503 in the studied PV patients and Dsg3-reactive healthy donors, we assessed whether these PV-associated HLA class II alleles restricted T cell recognition of the identified Dsg3 peptides. First, HLA class II restriction of the peptide DG3(96-112) was studied by coculturing a total of six TCC from three patients (clones PV7.3, PV10.1, PV10.2, and PV11.1) and a healthy control (Co1.1 and Co1.2) with HLA-matched B-LCL as APC and DG3(96-112) at a concentration of 10 µg/ml (Fig. 5). TCC PV7.3, PV10.1, and PV10.2 were stimulated by DG3(96-112) in the presence of DRB1*0402+ but not DQB1*0503+ or irrelevant (DRB1*0701+) APC (Fig. 5A). This proliferative response was uniformly inhibited by anti-DR moAb (Fig. 5B). In contrast, proliferation to DG3(96-112) of the TCC PV10.1, PV11.1, Co1.1, and Co1.2 was restricted to the presence of HLA-DQB1*0503+ APC (Fig. 5C) and was inhibited by anti-DQ moAb (Fig. 5D). Noteworthy, TCC PV10.2 recognized peptide DG3(96-112) in the presence of both HLA-DRB1*0402+ and DQB1*0503+ APC (Fig. 5, A and C).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 5. HLA class II restriction of the proliferative T cell response to the immunodominant Dsg3 peptide DG3(96-112). Shown is the proliferation of six DG3(96-112)-responsive TCC upon coculture with DRB1*0402, DQB1*0503, and DRB1*0701 homolozygous PBMC as APC (A and C) expressed as a SI which is the ratio of cpm in cultures with/without DG3(96-112). A SI >2 was considered to represent a significant proliferation; background proliferation ranged from 1361-2105 cpm. In addition, moAb against HLA-DR, -DQ, and -DP were added to cultures of the TCC with DG3(96-112) and either HLA-DRB1*0402+ APC (B) or HLA-DQB1*0503+ APC (D). Shown is the percentage of inhibition of T cell proliferation to DG3(96-112).

 
Identification of potential HLA class II binding motifs of the identified Dsg3 peptides

All of the Dsg3 peptides identified in the present study carried a positively charged amino acid (i.e., arginine or lysine) at the p4 anchor position while p1 contained a hydrophobic amino acid (isoleucine or valine). Most of the Dsg3 peptides carried another small hydrophilic (serine or threonine) or hydrophobic amino acid (valine) at p6 (Table III). Three-dimensional model structures for HLA-DRB1*0402 and DQB1*0503 in complex with the DG3(96-112) peptide were generated as described in Materials and Methods. Fig. 6 shows an electrostatic potential map projected onto the surface of these HLA class II molecules. In case of HLA-DRB1*0402, the DG3(96-112) peptide is displayed demonstrating the interaction of the positively charged aa (lysine) at position p4 with the negatively charged surface (P4 pocket) of the HLA class II allele; these negative charges arise from residues DRB 70 and 71 of HLA-DRB1*0402 (Fig. 6A). Although the electrostatic potential of this binding pocket of DQB1*0503 is different compared with DRB1*0402, peptide DG3(96-122) could be accommodated easily into the binding groove of this allele (Fig. 6B). The missing charges may be compensated by the amino acids Glu{alpha}11 and Asp{alpha}66 that are in the vicinity of this binding pocket.



View larger version (60K):
[in this window]
[in a new window]
  		FIGURE 6. Potential binding sites to HLA-DRB1*0402 (A) and HLA-DQB1*0503 (B) of the identified Dsg3 peptides. Electrostatic potential maps of the HLA-DRB1*0402 (A) and HLA-DQB1*0503 (B) model structures. In case of the HLA-DRB1*0402 allele, peptide DG3(96-112) is represented as a rod model. Nitrogen, oxygen, and carbon atoms are colored blue, red, and white. Red and blue-colored regions on the surface representation of the two alleles indicate negative and positive charged regions, respectively. Binding pockets for the different positions in the peptide (P1, P4, and P6) are indicated. In the HLA-DQB1*0503 molecule, the p4 pocket exhibits a neutral charge.

 
TCR V{beta} repertoire of Dsg3-reactive Th cell clones

In light of the differential responsiveness of autoreactive TCC to distinct Dsg3 peptides the TCRBV usage of a panel of DG3(96-112)-responsive TCC from three PV patients and a healthy donor was investigated by RT-PCR. Noteworthy, 2 of 5 TCC responsive to DG3(96-112) were TCRBV5 positive while the remaining TCC used several other TCRBV chains, i.e., V{beta}15, 18, and 19 (Table V). These findings suggest that the TCRBV usage of autoreactive TCC specific for a single Dsg3 peptide is rather heterogeneous.


View this table:
[in this window]
[in a new window]
  		Table V. TCR V{beta} usage of T cell clones responsive to DG3(96-112) from three PV patients and a healthy individual

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, T cell recognition of defined epitopes of the ECD of Dsg3 was studied in PV patients and in Dsg3-responsive healthy individuals. Upon selection by MACS cytokine secretion assay, Dsg3-specific Th responses were not only detected in a cohort of PV patients (irrespective of their clinical status) but also in healthy carriers of the PV-associated HLA class II alleles, DRB1*0402 and DQB1*0503. This finding confirms previous studies from our group supporting the idea that carriers of distinct HLA class II alleles are genetically at risk to develop Dsg3-specific T cell responses independent from the development of PV (21, 22).

Our findings demonstrate that a limited set of only eight Dsg3 peptides was recognized by the majority of the Dsg3-responsive TCC from both PV patients and healthy individuals that were characterized in the present study. Five peptides residing in the ECD 1–3 of Dsg3 were recognized by autoreactive Th1 and Th2 cells from both PV patients and healthy carriers of PV-associated HLA class II alleles (Fig. 2A). There was no direct relationship between T cell reactivity to a distinct epitope of Dsg3 and the clinical status of the PV patients. Noteworthy, peptide DG3(96-112) residing in the ECD1 of Dsg3 was recognized by the majority of TCC derived from both PV patients and Dsg3-responsive healthy donors. Two of the Dsg3 peptides identified in this study, DG3(205-221) and DG3(376-392), had already been identified by our group in previous studies: DG3(205-221) is highly homologous to peptide p33 (aa 210–226) which was recognized by T cells from a Dsg3-responsive healthy donor (21) and peptide DG3(376-392) is highly homologous to peptide p67 (aa 380–396) which was recognized by T cells from a DRB1*0402+ PV patient (30) (Table IV). The finding that most of the T cell peptides of Dsg3 are located in the first three ECD of Dsg3 is of interest since this region of the Dsg3 ectodomain harbors the major Ab epitopes (31). Two recent studies identified the NH2 terminus of Dsg3 (aa 1–161) as the major binding site for pathogenic autoAb (31, 32); within this region a stretch consisting of aa 25–88 was found to represent an immunodominant epitope for circulating autoAb (31). To map conformational epitopes of Dsg3, Dsg3-domain-swapped molecules and point-mutated Dsg3 molecules with Dsg1-specific residues were generated by baculovirus expression. The swapped domains were portions of the N-terminal ECD of Dsg3 (aa 1–566). The binding of autoAb to the mutant molecules was assessed by competition ELISAs. Domain-swapped molecules containing the N-terminal 161 residues of Dsg3 yielded >50% competition in 31 of 40 (77.5%) PV sera. Noteworthy, the T cell peptides DG3(78-94) and DG3(96-112) identified in the present study are fully contained within this NH2-terminal stretch of Dsg3.


View this table:
[in this window]
[in a new window]
  		Table IV. Sequence homology of identified Dsg3 T cell peptides with previously identified Dsg3 peptides

 
The present study demonstrates that all of the identified Dsg3 epitopes share common anchor residues at relative positions 1, 4, and 6. These amino acid motifs were previously identified by Wucherpfennig and coworkers (19, 33) to be potential HLA class II binding sites. Based on putative binding motifs of DRB1*0402 (which is prevalent in PV) (34), Wucherpfennig and colleagues (19, 33) proposed seven candidate T cell epitopes of Dsg3 that share amino acid residues at p1, 4, and 6 anchor positions (Table III). In their study, PBMC from four DRB1*0402 PV patients were only stimulated by two of these Dsg3 peptides, aa 190–204 and aa 206–220 (19). Dsg3 peptide aa 190–204 is homologous to peptide DG3(189-205) of the current study, the later Dsg3 peptide (aa 206–220) is homologous to peptide DG3(205-221) of this study and peptide aa 210–226 of the aforementioned study (30) (Table IV). Thus, the findings of the present study clearly extend the previous observations of Wucherpfennig and coworkers by demonstrating that autoaggressive T cells of PV patients do indeed recognize a limited set of Dsg3 peptides. Based on the findings of the present study with a larger cohort of PV patients, DG3(96-112) seems to be preferentially recognized by autoaggressive T cells and not DG3(206-220) as suggested by their previous findings (Fig. 3).

An independent study by Lin et al. (20) identified T cell responses from PV patients to three polypeptides (aa 145–192, aa 240–303, and aa 570–614) representing stretches of the ECD1–5 of Dsg3. Noteworthy, polypeptide aa 240–303 contains a peptide DG3(250-266) which was identified in the present study and by Wucherpfennig and coworkers (19). The Dsg3 peptide DG3(342-358) identified in the present investigation has not been described before as well as the peptide DG3(483-499) which was recognized by T cells from two healthy donors.

Epitope spreading is a common phenomenon found in chronic relapsing autoimmune disorders (35). Our findings suggest that intramolecular epitope spreading of Dsg3 T cell peptides does not occur once the disease is clinically apparent since there was no direct relationship between Dsg3 peptide reactivity and a distinct clinical phenotype (i.e., active vs remittent disease). A recent study (36) clearly demonstrated that epitope spreading occurs in pemphigus foliaceus (PF), a related autoimmune disorder associated with autoAb against Dsg1. Individuals who later developed fogo selvagem, an endemic variant of PF, were found to exhibit autoAb against nonpathogenic epitopes of Dsg1 in the preclinical stage. Once full-blown disease occurred, they had developed autoAb directed against a distant, pathogenic epitope of the ECD1 of Dsg1 (36). There is also evidence for intermolecular epitope spreading in pemphigus since patients with PV may develop PF later in the course of disease (37, 38). Also, PV patients with only mucosal lesions (associated with anti-Dsg3 IgG) may later on develop cutaneous lesions that are associated with autoAb against Dsg1, the autoantigen of PF (11). Along this line, it is possible that intermolecular epitope spreading in PV, as shown for the subsequent development of Dsg3- and Dsg1-specific autoAb can be explained by the cross-reactivity of autoreactive Th cells specific for distinct epitopes of Dsg3 with similar or identical epitopes of the Dsg1 ectodomain (39).

Noteworthy, despite the uniform generation of Dsg3-responsive TCC by in vitro stimulation of PBMC with recombinant Dsg3 protein followed by MACS separation, the proliferative response of the established TCC to recombinant Dsg3 protein and Dsg3 peptides varied (Fig. 4). Most (60%) TCC recognized both, Dsg3 and a distinct Dsg3 peptide. These TCC fulfill the criteria of "type A" peptide-specific T cells according to a recent classification (40). In contrast, a considerable fraction (40.2%) of the TCC showed only response to a distinct Dsg3 peptide (at lower concentrations than the aforementioned TCC) but did not mount a significant proliferative response to recombinant Dsg3 protein like "type B" T cells (40). Moreover, despite a vigorous response to the recombinant Dsg3 protein, some Dsg3-specific TCC were not stimulated by any of the used Dsg3 peptides. This may have several reasons: 1) a particular T cell epitope was not fully contained within a single peptide, 2) posttranslational modifications of Dsg3 were not conserved in the synthetic peptides (41), or 3) an immunodominant peptide-induced anergy of autoreactive high affinity TCC (42). This different Ag responsiveness of the generated TCC has to be kept in mind when interpreting the potential significance of the identified immunodominant T cell epitopes of Dsg3 which may be under-/overestimated. Moreover, T cell epitopes may have been missed due to this experimental approach.

Another major finding of this study was the demonstration of Dsg3 peptide T cell recognition in association with HLA-DRB1*0402 and DQB1*0503 (Fig. 5). These findings are consistent with epidemiological studies showing a strong association of PV with HLA-DRB1*0402 (16) and HLA-DQB1*0503 (17, 18) and a recent study from our group that identified Th cell responses to Dsg3 not only in PV patients but also in healthy carriers of the aforementioned PV-associated HLA class II alleles (22). These findings are in line with three independent studies demonstrating that Dsg3-specific TCC were restricted by HLA-DRB1*0402 (19, 20, 43). The DG3(96-112)-responsive TCC Co1.1 stained positive with a DG3(96-112)/DRB1*0402 tetramer but not with the DG3(250-266)/DRB1*0402 control tetramer providing direct evidence for the presentation of DG3(96-112) by HLA-DRB1*0402 (C. Veldman, R. Eming, and M. Hertl, unpublished observation).

In the present study, 3 of 4 PV patients (Table I) and 2 of 3 of the Dsg3-responsive healthy donors that did not express DRB1*0402 or DQB1*0503 were positive for HLA-DRB1*0301 (Table II). A previous study demonstrated that non-PV-associated HLA class II alleles such as DQB1*0301 restricted Dsg3-driven T cell responses (43). DQB1*0301 is homologous to the PV-associated DQB1*0503 which differs from the common DQB1*0501 allele only by a valine to aspartic acid substitution at putative peptide binding position DQB-chain position 57 (44, 45). These findings may explain why PV patients and healthy individuals who do not carry the "classical" PV-associated HLA class II alleles develop autoreactive T cell responses against Dsg3 (Table I and II).

Dsg3-reactive Th1 (21) and Th2 (20) cells were identified that recognized identical epitopes of the ECD of Dsg3 in the context of PV-associated HLA class II alleles. In a recent study, both Dsg3-autoreactive Th1 and Th2 cells were isolated from patients with acute onset, chronic active and remittent PV. The appearance of Dsg3-reactive Th2 was constant at the different disease stages while Dsg3-reactive Th1 cells were detected at a significantly higher frequency in chronic active PV which was associated with the highest autoAb titers. Noteworthy, the titers of serum autoAb against Dsg3 were directly correlated with the ratio of autoreactive Th1/Th2 cells suggesting that both, Th1 and Th2 cells may be critically involved in the regulation of autoAb production.

Peptide DG3(96-112) was recognized by several TCC in association with either, DRB1*0402 or DQB1*0503. Noteworthy, the TCC PV10.2 recognized DC3(96-112) in association with both, DR1B*0402+ and DQB1*0503+ APC. This finding suggests that both HLA class II alleles possess at least similar peptide binding motifs which is supported by the three dimensional model structures of these two alleles with the DG3(96-112) peptide. All of the identified Dsg3 peptides of the present study fit into the peptide binding groove of DRB1*0402 based on their positive charge at p4 which is complementary to the negatively charged P4 pocket of HLA-DRB*0402 (Fig. 6A). In DQB*0503, there is not such a negative charge at the P4 pocket (Fig. 6B). Based on the potential interactions of amino acid residues of the Dsg3 peptides at p1 and p6, peptide DG3(96-112) may act as a heteroclitic peptide in association with DQB1*0503. Cross-reactivity to similar or identical amino acid residues of DG3(96-112) which are presented by HLA-DQB1*0503 is also a possibility.

The heterogeneous TCR V{beta} usage of Dsg3 peptide-specific T cells found in the present study strongly suggests that a highly selective usage of a single TCR V{beta}-chain by T cells responsive to a distinct Dsg3 peptide is unlikely. This is also supported by the finding that the peptide affinity of the generated Dsg3-responsive TCC varied considerably (Fig. 4). In an independent study, TCC that responded to aa 145–192 of Dsg3 used the TCR V{beta}13 while TCC responsive to peptides aa 240–303 and aa 570–614 preferentially used TCR V{beta}7 and V{beta}17 genes, respectively (46). In a recent study with patients suffering from PF, a related autoimmune disorder directed against Dsg1, 10 of 17 autoreactive Dsg1-specific TCC expressed oligoclonal TCR V{beta} chains (47).

In summary, the findings of the present study strongly suggest 1) that autoreactive Th cells from PV patients (and healthy donors) using different TCR V{beta} recognize a limited set of identical Dsg3 peptides, 2) that T cell recognition of Dsg3 is restricted by distinct, i.e., PV-associated HLA class II alleles, and 3) that the identified peptides share potential HLA class II binding motifs. Thus, PV is the consequence of a loss of B cell rather than T cell tolerance. This is supported by the recent evidence for epitope spreading at the Ab level but not at the T cell level as demonstrated in the present study.


   Acknowledgments
 
We thank Dr. Masayuki Amagai (Department of Dermatology, Keio University, Tokyo, Japan) for recombinant PVhis (Dsg3) baculovirus, and Rüdiger Eming and Manfred Lutz for critical reading of the manuscript. We are also grateful to Astrid Mainka for expert help with the preparation of recombinant Dsg3 and the ELISA analysis of Dsg3 autoAb.


   Footnotes
 
1 This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 263-C15; He1602/6-1, to M.H. and SFB 263-C8, to R.W.), the Interdisciplinary Center for Clinical Research (C8, to R.W. and C9, to M.H.), and the ELAN Fonds (01.09.19.1, to C.V.) of the University of Erlangen-Nuremberg. Back

2 C.M.V. and K.L.G. contributed equally to this work. Back

3 Address correspondence and reprint requests to Dr. Michael Hertl, Department of Dermatology, University of Erlangen, Hartmannstrasse 14, 91052 Erlangen, Germany. E-mail address: Michael.Hertl{at}derma.imed.uni-erlangen.de Back

4 Abbreviations used in this paper: PV, pemphigus vulgaris; autoAb, autoantibody; Dsg3, desmoglein 3 (autoantigen of PV); Dsg1, desmoglein 1 (autoantigen of PF); ECD, extracellular domain; TCC, T cell clone; B-LCL, B lymphoblastoid cell line; SI, stimulation index; TCRBV, TCR V{beta} region; TCRBC, TCR conserved {beta} region; PF, pemphigus foliaceus. Back

Received for publication September 15, 2003. Accepted for publication December 19, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Amagai, M., V. Klaus-Kovtun, J. R. Stanley. 1991. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869.[Medline]
  2. Stanley, J. R.. 1989. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J. Clin. Invest. 83:1443.
  3. Amagai, M., S. Karpati, R. Prussick, V. Klaus-Kovtun, J. R. Stanley. 1992. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J. Clin. Invest. 90:919.
  4. Ding, X., V. Aoki, J. M. Mascaro, Jr, A. Lopez-Swiderski, L. A. Diaz, J. A. Fairley. 1997. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J. Invest. Dermatol. 109:592.[Medline]
  5. Anhalt, G. J., L. A. Diaz. 1989. In vivo studies of antibody dependent acantholysis. Immunol. Ser. 46:291.[Medline]
  6. Koch, P. J., M. G. Mahoney, H. Ishikawa, L. Pulkkinen, J. Uitto, L. Shultz, G. F. Murphy, D. Whitaker-Menezes, J. R. Stanley. 1997. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J. Cell Biol. 137:1091.[Abstract/Free Full Text]
  7. Nguyen, V. T., A. Ndoye, S. A. Grando. 2000. Pemphigus vulgaris antibody identifies pemphaxin: a novel keratinocyte annexin-like molecule binding acetylcholine. J. Biol. Chem. 275:29466.[Abstract/Free Full Text]
  8. Nguyen, V. T., A. Ndoye, S. A. Grando. 2000. Novel human {alpha}9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am. J. Pathol. 157:1377.[Abstract/Free Full Text]
  9. Kljuic, A., H. Bazzi, J. P. Sundberg, A. Martinez-Mir, R. O’Shaughnessy, M. G. Mahoney, M. Levy, X. Montagutelli, W. Ahmad, V. M. Aita, et al 2003. Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 113:249.[Medline]
  10. Huilgol, S. C., M. M. Black. 1995. Management of the immunobullous disorders. II. Pemphigus. Clin. Exp. Dermatol. 20:283.[Medline]
  11. Mahoney, M. G., Z. Wang, K. Rothenberger, P. J. Koch, M. Amagai, J. R. Stanley. 1999. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J. Clin. Invest. 103:461.[Medline]
  12. Ishii, K., M. Amagai, R. P. Hall, T. Hashimoto, A. Takayanagi, S. Gamou, N. Shimizu, T. Nishikawa. 1997. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J. Immunol. 159:2010.[Abstract]
  13. Jones, C. C., R. G. Hamilton, R. E. Jordon. 1988. Subclass distribution of human IgG autoantibodies in pemphigus. J. Clin. Immunol. 8:43.[Medline]
  14. Bhol, K., K. Natarajan, N. Nagarwalla, A. Mohimen, V. Aoki, A. R. Ahmed. 1995. Correlation of peptide specifity and IgG subclass with pathogenetic and nonpathogenetic autoantibodies in pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 92:5243.
  15. Amagai, M., T. Hashimoto, K. J. Green, N. Shimizu, T. Nishikawa. 1995. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J. Invest. Dermatol. 104:895.[Medline]
  16. Ahmed, A. R., E. J. Yunis, K. Khatri, R. Wagner, G. Notani, Z. Awdeh, C. A. Alper. 1990. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 87:7658.[Abstract/Free Full Text]
  17. Ahmed, A. R., R. Wagner, K. Khatri, G. Notani, Z. Awdeh, C. A. Alper, E. J. Yunis. 1991. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 88:5056.[Abstract/Free Full Text]
  18. Sinha, A. A., C. Brautbar, F. Szafer, A. Friedmann, E. Tzfoni, J. A. Todd, L. Steinman, H. O. McDevitt. 1988. A newly characterized HLA DQ {beta} allele associated with pemphigus vulgaris. Science 239:1026.[Abstract/Free Full Text]
  19. Wucherpfennig, K. W., B. Yu, K. Bhol, D. S. Monos, E. Argyris, R. W. Karr, A. R. Ahmed, J. L. Strominger. 1995. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 92:11935.[Abstract/Free Full Text]
  20. Lin, M. S., S. J. Swartz, A. Lopez, X. Ding, M. A. Fernandez-Vina, P. Stastny, J. A. Fairley, L. A. Diaz. 1997. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest. 99:31.[Medline]
  21. Hertl, M., M. Amagai, H. Sundaram, J. Stanley, K. Ishii, S. I. Katz. 1998. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J. Invest. Dermatol. 110:62.[Medline]
  22. Veldman, C., A. Stauber, R. Wassmuth, W. Uter, G. Schuler, M. Hertl. 2003. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J. Immunol. 170:635.[Abstract/Free Full Text]
  23. Nishifuji, K., M. Amagai, M. Kuwana, T. Iwasaki, T. Nishikawa. 2000. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J. Invest. Dermatol. 114:88.[Medline]
  24. Spaeth, S., R. Riechers, L. Borradori, D. Zillikens, L. Budinger, M. Hertl. 2001. IgG, IgA, and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. Br. J. Dermatol. 144:1183.[Medline]
  25. Manz, R., M. Assenmacher, E. Pfluger, S. Miltenyi, A. Radbruch. 1995. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. USA 92:1921.[Abstract/Free Full Text]
  26. Budinger, L., L. Borradori, C. Yee, R. Eming, S. Ferencik, H. Grosse-Wilde, H. F. Merk, K. Yancey, M. Hertl. 1998. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest. 102:2082.[Medline]
  27. Vriend, G.. 1990. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 8:52.[Medline]
  28. van Gunsteren, W. F., S. R. Billeter, A. A. Eising, P. H. Hühnenberger, P. Krüger, A. E. Mark, W. R. P. Scott, I. G. Tironi. 1996. Biomolecular Simulation: The GROMOS 96 Manual and User Guide vdf Hochschul-Verlag AG, Zuerich.
  29. Nicholls, A., K. A. Sharp, B. Honig. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281.[Medline]
  30. Riechers, R., J. Grotzinger, M. Hertl. 1999. HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris: review of the literature and potential applications for the development of a specific immunotherapy. Autoimmunity 30:183.[Medline]
  31. Sekiguchi, M., Y. Futei, Y. Fujii, T. Iwasaki, T. Nishikawa, M. Amagai. 2001. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J. Immunol. 167:5439.[Abstract/Free Full Text]
  32. Tsunoda, K., T. Ota, M. Aoki, T. Yamada, T. Nagai, T. Nakagawa, S. Koyasu, T. Nishikawa, M. Amagai. 2003. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J. Immunol. 170:2170.[Abstract/Free Full Text]
  33. Wucherpfennig, K. W., J. L. Strominger. 1995. Selective binding of self peptides of disease-associated major histocompatibility complex (MHC) molecues: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J. Exp. Med. 181:1597.[Free Full Text]
  34. Hammer, J., F. Gallazzi, E. Bono, R. W. Karr, J. Guenot, P. Valsasnini, Z. A. Nagy, F. Sinigaglia. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181:1847.[Abstract/Free Full Text]
  35. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:75.[Abstract/Free Full Text]
  36. Li, N., V. Aoki, G. Hans-Filho, E. A. Rivitti, L. A. Diaz. 2003. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J. Exp. Med. 197:1501.[Abstract/Free Full Text]
  37. Kawana, S., T. Hashimoto, T. Nishikawa, S. Nishiyama. 1994. Changes in clinical features, histologic findings, and antigen profiles with development of pemphigus foliaceus from pemphigus vulgaris. Arch. Dermatol. 130:1534.[Abstract]
  38. Harman, K. E., M. J. Gratian, P. J. Shirlaw, B. S. Bhogal, S. J. Challacombe, M. M. Black. 2002. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris. Br. J. Dermatol. 146:684.[Medline]
  39. Schafer, S., P. J. Koch, W. W. Franke. 1994. Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins. Exp. Cell Res. 211:391.[Medline]
  40. Pu, Z., J. A. Carrero, E. R. Unanue. 2002. Distinct recognition by two subsets of T cells of an MHC class II-peptide complex. Proc. Natl. Acad. Sci. USA 99:8844.[Abstract/Free Full Text]
  41. Pette, M., K. Fujita, D. Wilkinson, D. M. Altmann, J. Trowsdale, G. Giegerich, A. Hinkkanen, J. T. Epplen, L. Kappos, H. Wekerle. 1990. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. USA 87:7968.[Abstract/Free Full Text]
  42. Diepolder, H. M., M. C. Jung, E. Wierenga, R. M. Hoffmann, R. Zachoval, T. J. Gerlach, S. Scholz, G. Heavner, G. Riethmuller, G. R. Pape. 1996. Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro. J. Virol. 70:7540.[Abstract]
  43. Hertl, M., R. W. Karr, M. Amagai, S. I. Katz. 1998. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J. Invest. Dermatol. 110:388.[Medline]
  44. Kwok, W. W., G. T. Nepom, F. C. Raymond. 1995. HLA-DQ polymorphisms are highly selective for peptide binding interactions. J. Immunol. 155:2468.[Abstract]
  45. Nepom, B. S., G. T. Nepom, M. Coleman, W. W. Kwok. 1996. Critical contribution of {beta}-chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Proc. Natl. Acad. Sci. USA 93:7202.[Abstract/Free Full Text]
  46. Hacker, M. K., J. A. Fairley, M. Lin. 2003. T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris. J. Invest. Dermatol. 121:1365.[Medline]
  47. Moesta, A. K., M. S. Lin, L. A. Diaz, A. A. Sinha. 2002. T cell receptor {beta}-chain gene usage in endemic pemphigus foliaceus (fogo selvagem). J. Invest. Dermatol. 119:377.[Medline]



This article has been cited by other articles:


Home page
 Int ImmunolHome page
T. Ota, M. Aoki-Ota, K. Tsunoda, T. Nishikawa, S. Koyasu, and M. Amagai
Autoreactive B-cell elimination by pathogenic IgG specific for the same antigen: implications for peripheral tolerance
Int. Immunol., October 1, 2008; 20(10): 1351 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Takahashi, M. Amagai, T. Nishikawa, Y. Fujii, Y. Kawakami, and M. Kuwana
Novel System Evaluating In Vivo Pathogenicity of Desmoglein 3-Reactive T Cell Clones Using Murine Pemphigus Vulgaris
J. Immunol., July 15, 2008; 181(2): 1526 - 1535.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M. R Hussein, F. M. N. Ali, and A.-E. M M Omar
Immunohistological analysis of immune cells in blistering skin lesions
J. Clin. Pathol., January 1, 2007; 60(1): 62 - 71.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. R. Stanley and M. Amagai
Pemphigus, Bullous Impetigo, and the Staphylococcal Scalded-Skin Syndrome
N. Engl. J. Med., October 26, 2006; 355(17): 1800 - 1810.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Yang, N. A. Danke, D. Berger, S. Reichstetter, H. Reijonen, C. Greenbaum, C. Pihoker, E. A. James, and W. W. Kwok
Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein-Reactive CD4+ T Cells in Human Subjects.
J. Immunol., March 1, 2006; 176(5): 2781 - 2789.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Veldman, A. Pahl, S. Beissert, W. Hansen, J. Buer, D. Dieckmann, G. Schuler, and M. Hertl
Inhibition of the transcription factor foxp3 converts desmoglein 3-specific type 1 regulatory T cells into th2-like cells.
J. Immunol., March 1, 2006; 176(5): 3215 - 3222.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Thoma-Uszynski, W. Uter, S. Schwietzke, G. Schuler, L. Borradori, and M. Hertl
Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP230
J. Immunol., February 1, 2006; 176(3): 2015 - 2023.
[Abstract] [Full Text] [PDF]